SenesTech, Inc. (SNES) is a Materials stock trading at $1.21 (as of 2026-08-21), with a market capitalization of $6.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
SenesTech, Inc. develops a fertility-control approach to manage animal pest populations. Its ContraPest product is a liquid bait designed to limit the reproduction of both male and female rats, serving organizations involved in pest control.
Understand SenesTech, Inc.: how it makes money
SenesTech develops fertility-control pest management technology and sells ContraPest liquid bait to limit reproduction of male and female rats, earning money through commercial sales via channels such as direct-to-consumer, business-to-business, and retail distribution.
Commercial revenue growth is structurally tied to regulatory approvals and the company’s ability to expand retail and distribution availability, because ContraPest sale in states and distribution agreements drive where products can be sold.
Business quality (Weak): Limited segment and revenue visibility in the provided data, but there are concrete operating indicators tied to approvals, distribution, retail presence, and demonstrated efficacy.
Bull case
Regulatory and market access indicators are progressing: The company reports Evolve Approval for Sale in States of 44 (count) and Evolve Mouse Availability for Sale in States of 32 (count).
Distribution footprint appears meaningful: It reports 11 Active International Distribution Agreements and 23 Retail Co-Op and Big Box Chains With Current Agreements, with Retail Locations Represented of 50,000 (count).
Efficacy outcomes are strong in reported study results: It reports Evolve Efficacy Reduction in Litter Size After One Breeding Round of 61% and Evolve Efficacy Reduction in Litter Size Over Twelve Months of 90%.
Product and packaging efforts support differentiation: It reports Plastic Packaging Reduction From New Economy Size Pouch of 87%.
Bear case
Latest quarter shows no reported revenue: For the period 2026-03-31, reported revenue is 0.0B and operating margin is -429.8%.
Profitability is weak based on operating performance: Despite a reported gross margin of 68.6%, the operating margin is deeply negative at -429.8%.
Retail reach does not automatically translate into revenue in the provided quarter: The company reports 50,000 Retail Locations Represented (count) but still shows 0.0B revenue in the latest quarter provided.
If subscription-like engagement matters, retention could be a watch item: It reports Synestec Direct-to-Consumer Churn of 4.0% and Synestec Active Users in Subscription Program Share of 10.0%.